NEW HAVEN, Conn. — August 4, 2026 — Leads & Copy — Invivyd, Inc. (Nasdaq: IVVD) announced that on August 1, 2026, it granted options to purchase an aggregate of 277,500 shares of its common stock to ten newly hired non-executive employees. These options were granted as material inducements for the employees to join Invivyd.
The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and under the Invivyd, Inc. 2026 Inducement Plan. The exercise price for each option is $0.535, which was the closing price of Invivyd’s common stock on July 31, 2026, the last trading day before the grant date.
Each option will vest over a four-year period. Twenty-five percent of the shares subject to an option will vest on the first anniversary of the employee’s start date, with the remaining shares vesting in equal monthly installments thereafter. Vesting is contingent upon the employee’s continued service with Invivyd. The options have a 10-year term and are subject to the terms of the Invivyd, Inc. 2026 Inducement Plan.
Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2. The company utilizes a proprietary integrated technology platform, which is designed to assess, monitor, develop, and adapt to create best-in-class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) from its pipeline of innovative antibody candidates.
Source: Invivyd, Inc.
